fluorouracil has been researched along with Hepatic Veno Occlusive Disease in 19 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We enrolled 103 consecutive patients with stage III and high-risk stage II colorectal cancer treated with mFOLFOX6 (n = 37) or oral fluorouracil and leucovorin (n = 66) after curative surgery." | 3.85 | Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX. ( Hara, K; Iwai, T; Koizumi, M; Ohta, K; Shinji, S; Takahashi, G; Takeda, K; Uchida, E; Yamada, T; Yokoyama, Y, 2017) |
| " We investigated development of splenomegaly and its association with treatment outcome and genetic polymorphisms following adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in colorectal cancer (CRC) patients." | 3.83 | Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. ( Bang, YJ; Cha, Y; Han, SW; Im, SA; Kim, MJ; Kim, SH; Kim, TY; Lee, DW; Lee, KH; Oh, DY, 2016) |
| "In patients suffering from colorectal cancer liver metastases, 5-fluorouracil-based chemotherapy plus oxaliplatin ensures superior response rates at the cost of hepatic injury." | 3.75 | Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. ( Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Klinger, M; Koelblinger, C; Tamandl, D, 2009) |
| "A form of non-alcoholic steatohepatitis (NASH) related to chemotherapy and otherwise known as chemotherapy-associated steatohepatitis (CASH) is closely linked to irinotecan-based therapy and is associated with inferior outcomes following hepatic surgery mainly due to hepatic insufficiency and poor regeneration." | 2.45 | Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. ( Khan, AZ; Makuuchi, M; Morris-Stiff, G, 2009) |
| "Our study included 90 cases of colorectal cancer liver metastasis resected after preoperative chemotherapy." | 1.51 | Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis. ( Akagi, Y; Akiba, J; Fujita, F; Fukahori, M; Goto, Y; Hisaka, T; Ishikawa, H; Kawahara, R; Kinugasa, T; Miwa, K; Mizobe, T; Naito, Y; Nakashima, O; Nomura, Y; Okuda, K; Sakai, H; Tanaka, H; Tanigawa, M; Yano, H; Yasunaga, M, 2019) |
| "He subsequently developed sinusoidal obstruction syndrome (SOS) that resolved on discontinuation of XELOX treatment." | 1.43 | Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin. ( Chan, SH; Koo, SX; Ngeow, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 15 (78.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duwe, G | 1 |
| Knitter, S | 1 |
| Pesthy, S | 1 |
| Beierle, AS | 1 |
| Bahra, M | 1 |
| Schmelzle, M | 1 |
| Schmuck, RB | 1 |
| Lohneis, P | 1 |
| Raschzok, N | 1 |
| Öllinger, R | 1 |
| Sinn, M | 1 |
| Struecker, B | 1 |
| Sauer, IM | 1 |
| Pratschke, J | 1 |
| Andreou, A | 1 |
| Iwai, T | 1 |
| Yamada, T | 1 |
| Koizumi, M | 1 |
| Shinji, S | 1 |
| Yokoyama, Y | 1 |
| Takahashi, G | 1 |
| Takeda, K | 1 |
| Hara, K | 1 |
| Ohta, K | 1 |
| Uchida, E | 1 |
| Hubert, C | 1 |
| Lucidi, V | 1 |
| Weerts, J | 1 |
| Dili, A | 1 |
| Demetter, P | 1 |
| Massart, B | 1 |
| Komuta, M | 1 |
| Navez, J | 1 |
| Reding, R | 1 |
| Gigot, JF | 1 |
| Sempoux, C | 1 |
| Hisaka, T | 1 |
| Ishikawa, H | 1 |
| Sakai, H | 1 |
| Kawahara, R | 1 |
| Goto, Y | 1 |
| Nomura, Y | 1 |
| Yasunaga, M | 1 |
| Kinugasa, T | 1 |
| Fujita, F | 1 |
| Mizobe, T | 1 |
| Fukahori, M | 1 |
| Miwa, K | 1 |
| Nakashima, O | 1 |
| Tanigawa, M | 1 |
| Naito, Y | 1 |
| Akiba, J | 1 |
| Yano, H | 1 |
| Tanaka, H | 1 |
| Akagi, Y | 2 |
| Okuda, K | 1 |
| van den Broek, MA | 1 |
| Vreuls, CP | 1 |
| Winstanley, A | 1 |
| Jansen, RL | 1 |
| van Bijnen, AA | 1 |
| Dello, SA | 1 |
| Bemelmans, MH | 1 |
| Dejong, CH | 1 |
| Driessen, A | 1 |
| Olde Damink, SW | 1 |
| Robinson, SM | 3 |
| Mann, J | 3 |
| Vasilaki, A | 1 |
| Mathers, J | 1 |
| Burt, AD | 1 |
| Oakley, F | 3 |
| White, SA | 3 |
| Mann, DA | 3 |
| Manas, DM | 2 |
| Imai, K | 1 |
| Emi, Y | 1 |
| Iyama, KI | 1 |
| Beppu, T | 1 |
| Ogata, Y | 1 |
| Kakeji, Y | 1 |
| Samura, H | 1 |
| Oki, E | 1 |
| Maehara, Y | 1 |
| Baba, H | 1 |
| Koo, SX | 1 |
| Chan, SH | 1 |
| Ngeow, J | 1 |
| Kim, MJ | 1 |
| Han, SW | 1 |
| Lee, DW | 1 |
| Cha, Y | 1 |
| Lee, KH | 1 |
| Kim, TY | 2 |
| Oh, DY | 1 |
| Kim, SH | 1 |
| Im, SA | 1 |
| Bang, YJ | 1 |
| Volk, AM | 1 |
| Fritzmann, J | 1 |
| Reissfelder, C | 1 |
| Weber, GF | 1 |
| Weitz, J | 1 |
| Rahbari, NN | 1 |
| Lentschener, C | 1 |
| Nicco, C | 1 |
| Terris, B | 2 |
| Samama, CM | 1 |
| Coriat, R | 2 |
| Stevenson, HL | 1 |
| Prats, MM | 1 |
| Sasatomi, E | 1 |
| Chaput, U | 1 |
| Brezault, C | 1 |
| Chaussade, S | 1 |
| Khan, AZ | 1 |
| Morris-Stiff, G | 1 |
| Makuuchi, M | 1 |
| Klinger, M | 2 |
| Eipeldauer, S | 2 |
| Hacker, S | 1 |
| Herberger, B | 2 |
| Tamandl, D | 2 |
| Dorfmeister, M | 1 |
| Koelblinger, C | 1 |
| Gruenberger, B | 2 |
| Gruenberger, T | 2 |
| Kaczirek, K | 1 |
| Bibeau, F | 1 |
| Azria, D | 1 |
| Chateau, MC | 1 |
| Borrelly, C | 1 |
| Ychou, M | 1 |
| Quenet, F | 1 |
| Rouanet, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Construction and Evaluation of the Early Identification and Individualized Treatment for Oxaliplatin-induced Portal Hypertension[NCT04524676] | 25 participants (Anticipated) | Interventional | 2020-08-31 | Not yet recruiting | |||
| Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for fluorouracil and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemical and D | 2017 |
Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases.
Topics: Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive D | 2016 |
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2009 |
16 other studies available for fluorouracil and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2017 |
Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Dise | 2019 |
Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom | 2013 |
Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cell Cycle; Colorectal Neopla | 2013 |
The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemical and Drug Induced | 2013 |
Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2014 |
Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; | 2016 |
Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 2016 |
Response to 'Comment on 'The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome''.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Veno-Occ | 2016 |
Comment on 'The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome'.
Topics: Fluorouracil; Hepatic Veno-Occlusive Disease; Humans; Leucovorin; Neoplasms; Organoplatinum Compound | 2016 |
Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Topics: Actins; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protoco | 2017 |
[Sinusoidal obstruction syndrome induced by FOLFOX adjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 2008 |
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
[Vascular hepatic injury following neoadjuvant treatment for a cardial adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Female; Fluoroura | 2006 |